JP2020518240A - 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート - Google Patents

標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート Download PDF

Info

Publication number
JP2020518240A
JP2020518240A JP2019559009A JP2019559009A JP2020518240A JP 2020518240 A JP2020518240 A JP 2020518240A JP 2019559009 A JP2019559009 A JP 2019559009A JP 2019559009 A JP2019559009 A JP 2019559009A JP 2020518240 A JP2020518240 A JP 2020518240A
Authority
JP
Japan
Prior art keywords
endolysosomal
targeting
domain
protein
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019559009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518240A5 (https=
Inventor
オーバー，エリザベス・サリー・ウォード
オーバー，ライムンド・ヨハネス
カン，ジェフリー・チェ−ウェイ
スン，ウェイ
リ，ラン
Original Assignee
ザ テキサス エー アンド エム ユニバーシティー システム
ザ テキサス エー アンド エム ユニバーシティー システム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ テキサス エー アンド エム ユニバーシティー システム, ザ テキサス エー アンド エム ユニバーシティー システム filed Critical ザ テキサス エー アンド エム ユニバーシティー システム
Publication of JP2020518240A publication Critical patent/JP2020518240A/ja
Publication of JP2020518240A5 publication Critical patent/JP2020518240A5/ja
Priority to JP2023041511A priority Critical patent/JP7832906B2/ja
Priority to JP2025147594A priority patent/JP2026000961A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019559009A 2017-01-17 2018-01-17 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート Pending JP2020518240A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023041511A JP7832906B2 (ja) 2017-01-17 2023-03-16 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート
JP2025147594A JP2026000961A (ja) 2017-01-17 2025-09-05 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762447265P 2017-01-17 2017-01-17
US201762447411P 2017-01-17 2017-01-17
US62/447,411 2017-01-17
US62/447,265 2017-01-17
PCT/US2018/013952 WO2018136455A1 (en) 2017-01-17 2018-01-17 Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023041511A Division JP7832906B2 (ja) 2017-01-17 2023-03-16 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート

Publications (2)

Publication Number Publication Date
JP2020518240A true JP2020518240A (ja) 2020-06-25
JP2020518240A5 JP2020518240A5 (https=) 2021-02-25

Family

ID=62908641

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019559009A Pending JP2020518240A (ja) 2017-01-17 2018-01-17 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート
JP2023041511A Active JP7832906B2 (ja) 2017-01-17 2023-03-16 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート
JP2025147594A Pending JP2026000961A (ja) 2017-01-17 2025-09-05 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023041511A Active JP7832906B2 (ja) 2017-01-17 2023-03-16 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート
JP2025147594A Pending JP2026000961A (ja) 2017-01-17 2025-09-05 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート

Country Status (7)

Country Link
US (2) US11690919B2 (https=)
EP (1) EP3570894A4 (https=)
JP (3) JP2020518240A (https=)
CN (1) CN110944672A (https=)
AU (2) AU2018210912A1 (https=)
CA (1) CA3050692A1 (https=)
WO (1) WO2018136455A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020160310A1 (en) * 2019-01-30 2020-08-06 The Wistar Institute Of Anatomy And Biology Dna-encoded bispecific t-cell engagers targeting cancer antigens and methods of use in cancer theraputics
CN110893236A (zh) * 2019-10-09 2020-03-20 中山大学 溶酶体靶向的抗体药物偶联物及其应用
EP4228694A4 (en) * 2020-10-15 2024-12-18 Janux Therapeutics, Inc. ANTIBODIES DIRECTED AGAINST PSMA AND CD3 AND USES THEREOF
AU2021396172A1 (en) 2020-12-09 2023-07-06 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
CN112807444B (zh) * 2021-01-18 2023-12-12 北京大学深圳研究生院 一种纳米抗体药物偶联物
PT4288456T (pt) 2021-02-03 2024-11-13 Mythic Therapeutics Inc Anticorpos anti-met e suas utilizações
WO2022194078A1 (zh) * 2021-03-15 2022-09-22 北京大学 用于靶分子修饰的缀合物及其制备方法
US20250339571A1 (en) * 2021-08-27 2025-11-06 Actinium Pharmaceuticals, Inc. Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancer
WO2024046468A1 (en) * 2022-09-02 2024-03-07 Nanjing Legend Biotech Co., Ltd. Fusion proteins targeting lysosomal degradation pathway
CN118903457A (zh) * 2023-05-08 2024-11-08 中国科学院过程工程研究所 基于溶酶体的抗病毒制剂及其制备方法和用途
CN117659185B (zh) * 2023-12-06 2024-08-02 无锡傲锐东源生物科技有限公司 抗人Caldesmon蛋白单克隆抗体及其杂交瘤细胞株和应用
WO2025229338A2 (en) 2024-05-03 2025-11-06 University Of Southampton An antibody or antibody fragment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005523945A (ja) * 2002-04-26 2005-08-11 ザ ジェネラル ホスピタル コーポレーション アポトーシスのインビボにおける画像化
JP2009543876A (ja) * 2006-07-14 2009-12-10 アラビタ・ファーマシューティカルズ・インコーポレーテッド 再灌流障害の減弱
JP2011519367A (ja) * 2008-04-29 2011-07-07 ケンブリッジ エンタープライズ リミテッド 細胞死を検出しイメージングするための薬剤
WO2013081143A1 (ja) * 2011-11-30 2013-06-06 中外製薬株式会社 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
WO2015113476A1 (zh) * 2014-01-29 2015-08-06 上海恒瑞医药有限公司 配体-细胞毒性药物偶联物、其制备方法及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US20090181048A1 (en) 2007-06-08 2009-07-16 The Regents Of The University Of California Cancer drug delivery using modified transferrin
SG183867A1 (en) * 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
EP3680251A1 (en) * 2011-09-30 2020-07-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules for promoting elimination of antigens
EP2612864A1 (en) 2012-01-06 2013-07-10 University College Dublin Affinity tag system
CA2873112A1 (en) 2012-05-11 2013-11-14 Alexander Krantz Site-specific labeling and targeted delivery of proteins for the treatment of cancer
CA2871116A1 (en) * 2012-05-14 2013-11-21 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CN112587671A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
CA2895284A1 (en) * 2013-02-07 2014-08-14 Immunomedics, Inc. Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
KR20160043927A (ko) * 2013-03-14 2016-04-22 파카쉬 길 세포 표면 grp78에 결합하는 항체를 사용하는 암 치료
US20160031985A1 (en) 2013-03-15 2016-02-04 Katherine S. Bowdish Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
WO2015048724A1 (en) * 2013-09-30 2015-04-02 The University Of North Carolina At Chapel Hill Methods and compositions for self-assembly system of nanoparticles and microparticles for multi-targeting specificity
CN106459192B (zh) 2014-06-30 2021-08-03 默克专利股份公司 具有pH依赖性抗原结合的抗TNFa抗体
JP6967528B2 (ja) * 2016-04-04 2021-11-17 バイオベラティブ ユーエスエー インコーポレイテッド 抗補体Ｂｂ因子抗体及びその使用
JP7295799B2 (ja) 2016-12-02 2023-06-21 ザ テキサス エー アンド エム ユニバーシティー システム 抗原特異的抗体を選択的に枯渇させるための融合タンパク質

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005523945A (ja) * 2002-04-26 2005-08-11 ザ ジェネラル ホスピタル コーポレーション アポトーシスのインビボにおける画像化
JP2009543876A (ja) * 2006-07-14 2009-12-10 アラビタ・ファーマシューティカルズ・インコーポレーテッド 再灌流障害の減弱
JP2011519367A (ja) * 2008-04-29 2011-07-07 ケンブリッジ エンタープライズ リミテッド 細胞死を検出しイメージングするための薬剤
WO2013081143A1 (ja) * 2011-11-30 2013-06-06 中外製薬株式会社 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
WO2015113476A1 (zh) * 2014-01-29 2015-08-06 上海恒瑞医药有限公司 配体-细胞毒性药物偶联物、其制备方法及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOHOUT, S. C. ET AL., BIOCHEMISTRY, vol. 41, JPN6022005404, 2002, pages 11411 - 11424, ISSN: 0004707603 *
SCHUTTERS, K. ET AL., APOPTPSIS, vol. 15, JPN6022005402, 2010, pages 1072 - 1082, ISSN: 0004707602 *

Also Published As

Publication number Publication date
WO2018136455A1 (en) 2018-07-26
AU2025200221A1 (en) 2025-01-30
CN110944672A (zh) 2020-03-31
EP3570894A4 (en) 2021-04-07
EP3570894A1 (en) 2019-11-27
JP7832906B2 (ja) 2026-03-18
JP2023078292A (ja) 2023-06-06
US20230390413A1 (en) 2023-12-07
US11690919B2 (en) 2023-07-04
US20190381183A1 (en) 2019-12-19
JP2026000961A (ja) 2026-01-06
CA3050692A1 (en) 2018-07-26
AU2018210912A1 (en) 2019-08-15

Similar Documents

Publication Publication Date Title
JP7832906B2 (ja) 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート
CN114729041B (zh) 用于治疗多种实体瘤的靶向b7h3（cd276）的高亲和力纳米抗体
US20250295767A1 (en) Ror1-specific antigen binding molecules
AU2018302110B2 (en) Binding proteins 1
KR102355310B1 (ko) 인슐린-유사 성장 인자 1 수용체-특이적 항체 및 그의 용도
US20190374617A1 (en) Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polypeptides
Hong et al. Chemoenzymatic Synthesis of a Rhamnose‐Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy
CN106536555B (zh) 胰岛素样生长因子1受体特异性抗体及其用途
AU2014385799B2 (en) Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
Guo et al. Fusion of an albumin-binding domain extends the half-life of immunotoxins
US20200385428A1 (en) Cell/tissue-specific cell-penetrating antibodies
EP3000825A1 (en) Trans-tumoral peptide specific to neuropilin and fusion protein having same peptide fused therein
US20150174265A1 (en) Reversible masking of pore-forming proteins for macromolecular delivery
KR20220133944A (ko) 인간 혈액-뇌 장벽 표적화 항체
WO2026054854A2 (en) Light chain amyloid fibril antibodies, amyloid fibril and phagocyte targeting bi-specific phagocyte engagers, car-phagocytes, and uses thereof
WO2024119270A1 (en) Anti-transferrin receptor single domain antibodies, humanized antibodies, and recombinant constructs
BR112016020613B1 (pt) Anticorpos específicos para receptor de fator de crescimento semelhante à insulina tipo 1 e uso dos mesmos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220719

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221116